rotic plaques, (bilateral 1272; right 76; left 148) corresponding with an almost 5% higher prevalence of unilateral plaques left than right (P<0.0001). Mean carotid wall thickness was also higher on the left side compared to the right with respectively 2.9±1.3 mm and 3.12±1.2 mm (P<0.0001), whereas degree of stenosis did not differ. Plaques located in the right carotid artery had significantly more frequent calcification (42% vs 34%) as predominant component, suggesting a more stable phenotype, whereas on the left side, IPH (7% vs 10%), indicating a more vulnerable phenotype, and fibrous tissue (43% vs 47%) were significantly more prevalent. LRNC was equally distributed. Subjects with an atherosclerotic plaque on the left side have therefore an OR for IPH, fibrous tissue and calcification of 1.5, [0.9-1.4], 1.2, [1.1-1.4] and 0.7, [0.5-0.8], respectively. Conclusion: Although atherosclerosis is a systematic disease, we found an unequal distribution of carotid atherosclerotic plaque size and composition in the general population. IPH and fibrous tissue were more frequent observed in the left carotid artery, whereas calcification was more often present in the right. Our findings suggest that the predilection of cerebrovascular disease to the left side may be explained by the vulnerable phenotype of plaques in the left carotid artery.
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A composite peripheral blood gene expression score has high sensitivity for obstructive coronary artery disease in a non-invasive imaging population and correlates with plaque burden and morphology by Purpose: We previously validated a gene expression score (GES) comprising age, sex, and 23 genes for determining obstructive coronary artery disease (CAD, ≥50% stenosis) likelihood, measured by quantitative coronary angiography in an invasive angiography population. The GES validity in patients upstream in the referral path and the relationship with CT-angiography (CTA) parameters are unknown. Methods: Non-diabetic patients referred for myocardial perfusion imaging (MPI) were enrolled; before MPI, blood samples were obtained for GES. If clinically indicated, patients had invasive angiography; all others had research CTA to obtain anatomical information. CTAs were evaluated qualitatively by 2 independent readers and quantitatively by a validated protocol. Calcium scores (CAC, Agatston) were also evaluated. Results: A total of 431 patients had a GES score, MPI result, and either CT or invasive angiograms with 63 obstructive CAD cases. For MPI, 383 were negative. 48 were positive and 28 had invasive angiograms. For GES, ROC AUC was 0.79, with 46% below a pre-specified threshold of 15, where sensitivity and negative predictive value were 89 and 96%, respectively. Quantitative CTA analysis on 327 patients showed the GES was most highly correlated with non-calcified plaque (r=0.33, p<0.001). Detailed GES analysis showed neutrophil gene upregulation correlated with CAC (S100A8, S100A12, p<0.01), whereas neutrophil upregulation and lymphocyte down-regulation correlated with plaque burden (S100A12, CD3D, P<0.01). Conclusions: A composite peripheral blood GES had high sensitivity to obstructive CAD and most significantly correlated with non-calcified plaque. Neutrophil and lymphocyte selective gene expression correlated with overall plaque burden whereas only the former was associated with CAC. The pathophysiology of Cardiac Syndrome X (CSX) is still unclear, but most patients with CSX have endothelial dysfunction. It has been shown that adropin uniquely effects the regulation of endothelial function. The purpose of the study was to evaluate the role of adropin in CSX. 86 consecutive Cardiac Syndrome X-diagnosed patients and 86 age-sex matched healthy subjects were enrolled into the study. Serum adropin levels, nitrite/nitrate levels were measured in each subject. The baseline characteristic properties of study patients showed no significant differences between the two groups with respect to sex distribution, age, fasting glucose, serum creatinine, total cholesterol, LDL-C, HDL-C, triglyceride and mean platelet volume (p>0.05 for all). The history rate of diabetes mellitus and hypertension were significantly higher in the CSX than the control group (respectively, 34.9% to 15.1%, p=0.002 for diabetes mellitus and 46.5% to 29.1%, p=0.01 for hypertension). The adropin levels were significantly lower in CSX patients than healthy subjects (1.7±0.8 ng/mL and 3.4±1.8 ng/mL, respectively; p<0.001). The BMI values of CSX patients were significantly higher than control subjects (28.1±2.4 kg/m 2 and 26.0±3.7 kg/m 2 , respectively; p<0.001). Plasma nitrite/nitrate levels were lower in patients with CSX than control subjects (15.9±1.6 μmol/L vs 25.4±2.8 μmol/L, respectively; p<0.001) and they have a significantly positive correlation with plasma adropin levels (r=0.463, p<0.001). In the multiple linear regression analysis, nitrite/nitrate levels, BMI, and adropin were found to be independent risk factors for CSX (Table 1) . A ROC curve is used to identify the ability of adropin levels to predict the cardiac syndrome X. The area under the ROC curve was 0.854 for adropin levels (P = 0.0001). The sensitivity and specificity values of adropin levels were 90.7% and 70.9% respectively (cut off value 2.73). In conclusion, lower serum adropin levels were associated with CSX. Adropin is an independent risk factor for CSX. 
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